Sun Yat-sen University: Nasopharyngeal Carcinoma trials

The registry lists 207 Nasopharyngeal Carcinoma studies with Sun Yat-sen University as lead sponsor. 84 are open to participants now and 2 have results posted.

Early Phase 1 1Phase 1 11Phase 2 87Phase 3 70No phase 48(a study in two phases counts in both)

Studies

Page 1 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal CarcinomaNot yet recruitingNCT07824856Phase 2
• Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal CarcinomaRecruitingNCT07796789Phase 3
• Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II StudyNot yet recruitingNCT07756190Phase 2
• Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT07706985Phase 3
• Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid TumorsRecruitingNCT07584499Phase 1
• Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal CarcinomaNot yet recruitingNCT07567742Phase 2
• Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal CarcinomaNot yet recruitingNCT07555860Phase 2
• GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.Not yet recruitingNCT07540390Phase 3
• Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07388758Phase 2
• Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT07362979Phase 2
• LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPCRecruitingNCT07325539Phase 2
• Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.Not yet recruitingNCT07320963Phase 1/2
• EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07138989Phase 2
• Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal CarcinomaNot yet recruitingNCT07110558Phase 2
• Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical TrialRecruitingNCT07101744Phase 2
• Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT07064902Phase 2
• TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical TrialNot yet recruitingNCT06987123Phase 2
• TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal CarcinomaRecruitingNCT06912711Phase 2
• PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal CarcinomaNot yet recruitingNCT06900218Phase 3
• GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.RecruitingNCT06851247Phase 2
• Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRIRecruitingNCT06831357
• A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)RecruitingNCT06829147
• EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal CarcinomaRecruitingNCT06802835Phase 1/2
• QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Phase 3
• Treatment with Intensity Modulated Radiotherapy on the Change of Cognitive Function in Nasopharyngeal Carcinoma Patients: a Prospective Cohort StudyNot yet recruitingNCT06695936
• Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.RecruitingNCT06675214Phase 3
• Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal CarcinomaRecruitingNCT06669611Phase 3
• Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPCRecruitingNCT06657690Phase 2
• Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal CarcinomaRecruitingNCT06611150Phase 1
• GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal CarcinomaNot yet recruitingNCT06605131Phase 2
• TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT06561763Phase 3
• Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.RecruitingNCT06533267Not applicable
• Online Adaptive Radiotherapy for Nasopharyngeal CarcinomaRecruitingNCT06516133Phase 3
• The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving RadiotherapyRecruitingNCT06472739Phase 2
• GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06455410Phase 2
• Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal CarcinomaRecruitingNCT06445088
• KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical TrialNot yet recruitingNCT06370026Early Phase 1
• Artificial Intelligence-supported Reading Versus Standard Double Reading for the Interpretation of Magnetic Resonance Imaging in the Detection of Local Recurrence for Nasopharyngeal Carcinoma: a Randomised Controlled Multicenter StudyNot yet recruitingNCT06356441
• Adebrelimab and Chemoradiotherapy in High-risk LANPCRecruitingNCT06349889Phase 2
• SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal CarcinomaRecruitingNCT06323239Phase 2
• De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06313450Not applicable
• TPC Versus GP Induction Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06301165Phase 2
• Individualized Elective Neck Irradiation in NPC PatientsRecruitingNCT06241612Phase 3
• A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)RecruitingNCT06241599Phase 2/3
• Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Phase 3
• Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPCRecruitingNCT06197776
• The Effect of Sodium Fluoride Application on the Prevention of Radiation Caries in NPC PatientsNot yet recruitingNCT06174012Phase 2
• Occurrence of Radiation-induced Otitis Media in Nasopharyngeal Carcinoma Patients After Intensity Modulated RadiotherapyRecruitingNCT06170021
• Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction ChemotherapyRecruitingNCT06092957Phase 3
• Prospective Observational Study to Predict Severe Oral Mucositis Associated With Chemoradiotherapy in Nasopharyngeal Carcinoma Based on Deep LearningRecruitingNCT06032767
• IC Plus Low-dose Radiation Plus Cadonilimab in LANPCRecruitingNCT05941741Phase 3
• Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT05913414Phase 2
• Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal CarcinomaRecruitingNCT05877872Phase 3
• Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPCRecruitingNCT05854849Phase 3
• A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPCNot yet recruitingNCT05780294Phase 3
• A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and ChemotherapyNot yet recruitingNCT05622474Not applicable
• Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPCRecruitingNCT05549466Phase 2
• Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma ScreeningRecruitingNCT05447169
• A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPCNot yet recruitingNCT05433597Phase 2/3
• Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal CarcinomaRecruitingNCT05431764Phase 2
• Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter StudyNot yet recruitingNCT05417139Phase 2
• Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.RecruitingNCT05397769Phase 2
• Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal CarcinomaRecruitingNCT05352321Not applicable
• Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal CarcinomaRecruitingNCT05342792Phase 3
• PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT05341193Phase 1/2
• Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III TrialRecruitingNCT05340491Phase 3
• Ovarian Function of Nasopharyngeal Carcinoma Women SurvivorsNot yet recruitingNCT05183724
• Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal CarcinomaRecruitingNCT04944914Phase 3
• An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPCNot yet recruitingNCT04890522Phase 2/3
• Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal CarcinomaRecruitingNCT04778956Phase 3
• Umbrella Biomarker-Guided Therapy in NPCNot yet recruitingNCT04605562Phase 2
• Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPCRecruitingNCT04544969
• A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiationNot yet recruitingNCT04534855Phase 2
• Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal CarcinomaRecruitingNCT04453826Phase 3
• Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal CarcinomaRecruitingNCT04453813Phase 3
• Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal CarcinomaRecruitingNCT04448522Phase 3
• Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With MalnutritionRecruitingNCT04436965Phase 3
• Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal CarcinomaRecruitingNCT04425265Not applicable
• Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal CarcinomaRecruitingNCT04136886Phase 3
• PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma PatientsRecruitingNCT03907826Phase 3
• CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and RadiotherapyNot yet recruitingNCT03529279Phase 3
• Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPCNot yet recruitingNCT03503136Phase 3
• Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma PatientsRecruitingNCT03353467Not applicable
• Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal CarcinomaRecruitingNCT02610010Phase 3
• Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With ChemoradiotherapyCompletedNCT00700440Phase 2Results posted
• To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal CancerCompletedNCT00697619Phase 2Results posted
• Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.Active, not recruitingNCT07201337Phase 3
• Regulation of Blood-Brain Barrier Permeability by APOE Gene Polymorphism and Its Impact on Cognitive Function Post-Radiotherapy in Nasopharyngeal Carcinoma: an MRI StudyActive, not recruitingNCT06881225
• Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT06712888Phase 3
• TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT06664983Phase 3
• Methylation-specific PCR Test for Early Screening and Early Diagnosis of Nasopharyngeal CarcinomaCompletedNCT06367049
• Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal CarcinomaActive, not recruitingNCT05979961Phase 3
• Patients with Stage III-IVa Nasopharyngeal Carcinoma with or Without a Mobile Medical Platform Full-course Nutritional InterventionCompletedNCT05834712Not applicable
• Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal CarcinomaActive, not recruitingNCT05780372Phase 3
• CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPCStatus unknownNCT05724355Phase 2
• Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)Active, not recruitingNCT05587374Phase 3
• Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled TrialActive, not recruitingNCT05531916Not applicable
• SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05524168Phase 2
• Combining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC PatientsCompletedNCT05389306Not applicable
• Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal CarcinomainActive, not recruitingNCT05304468Phase 3